Updates of biological agents in the treatment of pediatric lupus nephritis
10.3760/cma.j.cn101070-20210721-00860
- VernacularTitle:儿童狼疮性肾炎的生物制剂治疗现状
- Author:
Gaofu ZHANG
1
;
Mo WANG
Author Information
1. 重庆医科大学附属儿童医院肾内科，国家儿童健康与疾病临床医学研究中心，儿童发育疾病研究教育部重点实验室，儿科学重庆市重点实验室，重庆 400014
- Keywords:
Systemic lupus erythematosus;
Lupus nephritis;
Child;
Biological agents;
Treatment
- From:
Chinese Journal of Applied Clinical Pediatrics
2021;36(17):1296-1300
- CountryChina
- Language:Chinese
-
Abstract:
Systemic lupus erythematosus (SLE) is an autoimmune disease involving multiple systems and organs.Lupus nephritis (LN) is the most common and serious complication of SLE, which is an important cause of end-stage renal disease and death in children.With the in-depth exploration of the immune pathogenesis of SLE, the greatly accelerated development of biological agents significantly improve the prognosis of pediatric LN.This study aims to review the current situation of biological agents in the treatment of pediatric LN, which provides references for optimizing the clinical therapeutic strategies of pediatric LN.
